United States - English - NLM (National Library of Medicine)

bidachem s.p.a. - bromhexine hydrochloride (unii: yc2zom3z8v) (bromhexine hydrochloride - unii:yc2zom3z8v) - bromhexine hydrochloride 1000 g in 1000 g

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - bromhexine hydrochloride 8mg;   - tablet - 8 mg - active: bromhexine hydrochloride 8mg   excipient: lactose monohydrate magnesium stearate maize starch - for use as a mucolytic to break down mucus and help clear the chest in conditions accompanied by excessive mucus secretions, such as in the common cold, influenza, infections of the respiratory tract or in other conditions where excess mucus is produced.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - bromhexine hydrochloride 1.6 mg/ml;   - oral solution - 1.6 mg/ml - active: bromhexine hydrochloride 1.6 mg/ml   excipient: benzoic acid cherry flavour 96323-33 chocolate flavour 96534-33 maltitol menthol purified water sucralose - breaks down mucus making it easier to cough up. its double strength formula relieves stubborn chesty coughs and breathing difficulties due to excess mucus in cold, flu and respiratory tract infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - bisacodyl 5mg;   - enteric coated tablet - 5 mg - active: bisacodyl 5mg   excipient: acacia carnauba wax castor oil glycerol iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate   maize starch as 8.3mg dried starch and 1.5mg soluble starch methacrylic acid copolymer purified talc shellac sucrose titanium dioxide white beeswax

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - bisacodyl 10mg;   - suppository - 10 mg - active: bisacodyl 10mg   excipient: hard fat

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - bisacodyl 5mg - suppository - 5 mg - active: bisacodyl 5mg excipient: hard fat

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - bisacodyl 5mg; bisacodyl 10mg; citric acid monohydrate 13.5 g; heavy magnesium carbonate 7.5 g - combination - active: bisacodyl 5mg excipient: acacia carnauba wax dibutyl phthalate glycerol iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate   maize starch methacrylic acid copolymer purified talc shellac sucrose titanium dioxide white beeswax active: bisacodyl 10mg excipient: hard fat active: citric acid monohydrate 13.5 g heavy magnesium carbonate 7.5 g

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - sodium picosulfate monohydrate 2.593mg equivalent to to 2.5 mg sodium picosulphate anhydrous - soft gelatin capsule - 2.5 mg - active: sodium picosulfate monohydrate 2.593mg equivalent to to 2.5 mg sodium picosulphate anhydrous excipient: gelatin glycerol macrogol 400 propylene glycol purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - nicoboxil 1.08%{relative}; nonivamide 0.17%{relative} - topical cream - active: nicoboxil 1.08%{relative} nonivamide 0.17%{relative} excipient: cetostearyl alcohol decyl oleate emulgade f liquid paraffin macrogol stearate 2500 parfumol krauter 0/065242 - herbal perfume oil. purified water sorbic acid stearic acid

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - meloxicam 7.5mg - tablet - 7.5 mg - active: meloxicam 7.5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium citrate dihydrate - · symptomatic treatment of painful osteoarthritis (arthrosis, degenerative joint disease). · symptomatic treatment of rheumatoid arthritis. in patients for whom longer-term use may be required, treatment efficacy should be reviewed within the first month of treatment and mobic withdrawn if there is a lack of therapeutic benefit. patients on long-term treatment should be reviewed regularly, such as every three months with regards to efficacy, risk factors and the ongoing need for treatment. the decision to prescribe a selective cox-2 inhibitor should only be made after assessment of the individual patient's overall risk for developing severe adverse events e.g. history of cardiovascular, renal, or gastrointestinal disease, and after use of alternative therapies such as non-pharmacological interventions and simple analgesic therapy where these have been found to lack analgesic efficacy or to have unacceptable adverse effects.